Other Information.
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement (as defined in Item 408(a) of Regulation S-K) or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
−Removed: Sixth Amendment to and Waiver Under Credit Agreement, dated as of August 8, 2025, by and among Harvard Bioscience, Inc., Citizens Bank, N.A., in its capacity as the administrative agent, and the lenders party thereto.
−Removed: Exhibit to the Current Report on Form 8-K (filed August 11, 2025) and incorporated by reference thereto.
−Removed: Certification of Principal Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
+Added: Second Amended and Restated Certificate of Incorporation of Harvard Bioscience, Inc.
+Added: (previously filed as an exhibit to the Company’s Registration Statement on Form S-1/A (File No.
+Added: 333-45996) (filed November 9, 2000) and incorporated by reference thereto).
+Added: Certificate of Amendment to Second Amended and Restated Certificate of Incorporation of Harvard Bioscience, Inc.
+Added: (previously filed as an exhibit to the Company’s Current Report on Form 8-K (filed March 6, 2026) and incorporated by reference thereto).
+Added: Amended and Restated By-laws of Harvard Bioscience, Inc.
+Added: (previously filed as an exhibit to the Company’s Registration Statement on Form S-1/A (File No.
+Added: 333-45996) (filed November 9, 2000) and incorporated by reference thereto).
+Added: Amendment No.
+Added: 1 to Amended and Restated Bylaws of Harvard Bioscience, Inc.
+Added: (as adopted October 30, 2007) (previously filed as an exhibit to the Company’s Current Report on Form 8-K (filed November 1, 2007) and incorporated by reference thereto).
+Added: Amendment No.
+Added: 2 to Amended and Restated Bylaws of Harvard Bioscience, Inc.
+Added: (as adopted January 19, 2026) (previously filed as an exhibit to the Company’s Current Report on Form 8-K (filed January 20, 2026) and incorporated by reference thereto).
+Added: Employment Agreement by and between Harvard Bioscience, Inc.
+Added: and John Duke, dated March 6, 2026 (previously filed as an exhibit to the Company’s Current Report on Form 8-K (filed March 10, 2026) and incorporated by reference thereto).
+Added: Employment Agreement by and between Harvard Bioscience, Inc.
+Added: and Mark Frost, dated March 6, 2026 (previously filed as an exhibit to the Company’s Current Report on Form 8-K (filed March 10, 2026) and incorporated by reference thereto).
+Added: Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: Certification of Chief Executive Officer of Harvard Bioscience, Inc., pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer of Harvard Bioscience, Inc., pursuant to 18 U.S.C.
12 unchanged sentences
HARVARD BIOSCIENCE, INC.
−Removed: November 6, 2025
/s/ JOHN DUKE
1 unchanged sentence
/s/ MARK FROST
−Removed: Interim Chief Financial Officer
+Added: Chief Financial Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.